



November 09, 2022

To

**BSE Limited**

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai – 400 001

Tel: 022 - 2272 1233 /4

Fax: 022 – 22721919

Ref: Aragen Life Sciences Private Limited

Scrip Code: 973783

ISIN: INE483I07010

**Sub: Publication of Extract of Financial Results in an English national daily newspaper**

In compliance with Regulation 52 (8) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has, on Wednesday, 09<sup>th</sup> November, 2022, published in “The Economic Times”, an English national daily newspaper, an extract of its Financial Results for the quarter and the half year ended 30<sup>th</sup> September, 2022, which were approved by its Board of Directors and disseminated on Monday, 07<sup>th</sup> November 2022 to the stock exchange BSE Limited, where the debt securities of the Company are listed. A copy of the newspaper cutting is enclosed herewith.

Please take on your records.

**For Aragen Life Sciences Private Limited**

KASTURI | Digitally signed by  
RAMAKRISHNA | KASTURI  
NA | RAMAKRISHNA  
Date: 2022.11.09  
19:01:43 +05'30'

**Ramakrishna Kasturi**

Company Secretary & Compliance Officer

growth has  
gle digits in  
ter of FY23  
is expected i  
vember.

Exporters  
exports of p  
chinery and  
pliances wo

Sug  
Def

Mills ba  
forward  
in Sept a

Pune: Many  
red forward  
October bef  
creased 5-6%  
on their exp  
nefit of hig  
ters of the c  
"Sugar exp  
defaults on  
sugar mills  
not good for  
the global m  
president (t

Free  
Free flow

Twe:  
@time

New Delhi:  
asked states  
al Highway  
encroachme  
port minist  
letter to sta  
directing th  
croachment  
that fall in th  
The letter, s  
that the NH  
croached up  
vegetable se  
pacting free  
leading to ro  
"Encroach  
whether of p  
or of a temp  
matter of g  
traffic mana  
ations and  
tion projec  
noted.

Officers o  
Highway Au  
(NHAI) are e

# ARAGEN LIFE SCIENCES PRIVATE LIMITED

(formerly known as GVK Biosciences Private Limited)

CIN: U74999TG2000PTC035826



Registered and Corporate Office: Plot 28A, IDA Nacharam, Hyderabad  
Telangana-500076, India  
Tel: +91 40 6692 9999 F: +91 40 6692 9900  
Email id: compliances@aragen.com, website:www.aragen.com

## Extract of standalone financial results for the quarter and half year ended 30 September 2022 (₹ in million)

S. No.	Particulars	Quarter ended		Half year ended		Year ended
		30 September 2022	30 September 2021	30 September 2022	30 September 2021	31 March 2022
		Unaudited	Unaudited	Unaudited	Audited	Audited
1	Total Income from operations	3,917.07	3,391.86	7,699.88	5,957.31	12,359.68
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	865.31	862.09	1,579.14	1,360.51	2,773.55
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	865.31	862.09	1,579.14	1,360.51	2,773.55
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	635.42	660.20	1,171.92	1,028.03	2,109.78
5	Total Comprehensive Income for the period	412.35	706.34	651.11	1,028.29	2,120.18
6	Paid up Equity Share Capital	681.38	681.38	681.38	681.38	681.38
7	Reserves (excluding Revaluation Reserve)	--	--	--	--	9,748.52
8	Securities Premium Account	391.33	391.33	391.33	391.33	391.33
9	Net worth	10,499.93	9,292.85	10,499.93	9,292.85	10,429.90
10	Paid up Debt Capital/ Outstanding Debt	4,898.69	2,230.33	4,898.69	2,230.33	5,204.54
11	Outstanding Redeemable Preference Shares	N.A.	N.A.	N.A.	N.A.	N.A.
12	Debt Equity Ratio*	0.47	0.24	0.47	0.24	0.50
13	Earnings Per Share (EPS) (Face value of ₹10 each fully paid)*					
	Basic EPS (Rs)	9.44	9.83	17.40	15.35	31.42
	Diluted EPS (Rs)	9.33	9.75	17.20	15.19	31.06
14	Capital Redemption Reserve	3.36	3.36	3.36	3.36	3.36
15	Debenture Redemption Reserve	200.00	N.A.	200.00	N.A.	200.00
16	Debt Service Coverage Ratio*	4.03	5.66	3.79	4.71	4.08
17	Interest Service Coverage Ratio*	9.41	23.17	8.67	17.36	13.19

\* Ratios for the quarter/half year ended have not been annualised.

\* EPS not annualised for the quarter/half year ended.

### Notes:

- The above is an extract of the detailed format of quarterly/half yearly/annual financial results filed with the stock exchange under Regulation 52 of the Listing Regulations as the company's debt securities are listed. The full format of the quarterly/half yearly/annual financial results are available on the websites of the stock exchange- BSE Limited at www.bseindia.com and the company at www.aragen.com.
- For the other line items referred in Regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the stock exchange, BSE Limited, and can be accessed at www.bseindia.com.
- The above standalone financial results for the quarter and Half year ended 30 September 2022 ("the statements") which are published in accordance with Regulation 52 of the LODR Regulations, have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 7th November 2022.
- The Company has started publishing quarterly results from quarter ended 31 March 2022 and hence quarterly figures for the quarter ended 30 September 2021 were neither reviewed nor subjected to audit, however, the management has exercised necessary due diligence to ensure that the financial results for this period provide a true and fair view of the Company's affairs.

For Aragen Life Sciences Private Limited

Sd/-

Manmahesh Kantipudi  
Director & CEO  
DIN: 05241166

Date : 7<sup>th</sup> November, 2022

Place : Hyderabad